Why do so many people lack access to healthcare?
Millions of people living with diabetes?and rare blood disorders?cannot?get the life-saving?medicine?they need.?In some?instances, medicine?is too costly, or?travelling to see the doctor or to pick up a prescription requires a long journey and a loss of wages.?
In extreme situations, there is no doctor?to see, healthcare?clinic?to go to, or medicine on?the?shelf at the pharmacy.?
The stark reality is that only a fraction of patients?are?being treated today – and we need to close that gap so that?people?have affordable access to the medicines we manufacture and the care they need.?
The?barriers?are?complex?and?differ?from country to country,?but we?know from experience that change is possible.
Our ambition is to provide access to?the medicines we have available, to the greatest number of?people?living with?diabetes,?rare blood?diseases?and?rare endocrine disorders, while addressing varying levels of affordability.?
In?low- and middle-income countries,?we?put extra?focus?on?the most vulnerable?people living with diabetes. In more than two-thirds?of the countries where we operate, we have established affordability and access programmes?to help patients in need.?
These programmes are working to answer tough questions, like:
How do we encourage more patients to enrol in affordability programmes?
How?do we design?insulins that don’t require cooling and can therefore travel further?
How can we simplify?medicine?supply chains to drive down price?
We are working on these questions?with a strong?commitment?to?making insulin available to all.?Read on and?learn more about our commitment to affordable?treatment and access to?diabetes?care.?
In?some?countries,?people living with?haemophilia?may be in a situation where they are not authorised to store their haemophilia medication at home. For example, during the?COVID-19 crisis,?they?have not been able to?visit hospitals to seek treatment.?
When people living with a rare blood disease face these situations, we work with local health authorities and partner organisations to provide financial support?for medicine and treatment?home delivery.?
To ensure clear and transparent relationships, our initiatives are designed in dialogue with policy makers,?for?support services?related to patient?training, delivery and?medicine?storage.
Americans?using our $25 low-cost insulin programme.
people with diabetes?treated with our human insulin at a maximum of?USD 3 per 10ml vial.
people?using our?diabetes care products globally.
people with haemophilia and family members benefitting?from educational activities?led by the?Novo Nordisk Haemophilia Foundation.